TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02571491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: 50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: at doses of 0.3 mcg / kg / min during and until the end of the surgical operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: at doses of 0.3 mcg / kg / min during and until the end of the surgical operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride
Description: at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine hydrochloride
Description: at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
Study: NCT02607046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The exercise program includes supervised and home-based walking and strength exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES
Description: This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
Study: NCT01211834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously over 1 hour infusion every 4weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMARDs
Description: Methotrexate(MTX) and/or 1 DMARDs
Study: NCT00842088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1001
Description: HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
Study: NCT04462133

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
Description: Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
Description: Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results
Study: NCT00789568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride
Description: 20 mg/kg and 100 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride
Description: 20 mg/kg and 100 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Moxifloxacin placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Moxifloxacin placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Moxifloxacin placebo tablet
Study: NCT04427930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JOINTSTEM
Description: Autologous Adipose Tissue derived MSCs
Study: NCT00247130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Study: NCT02235337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 400mg daily
Study: NCT01585831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1%
Description: Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
Study: NCT01921036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cardiac rehabilitation
Description: mutifactoral cardiac rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined exercise
Description: Moderate endurance and resistance exercise once a week over six months
Study: NCT00517257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg orally once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally once daily for 24 weeks
Study: NCT02494310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy Imaging
Description: Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy Imaging
Description: Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
Study: NCT04123483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EnBrace HR Softgel
Description: Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
Study: NCT04095377

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.
Study: NCT01238211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT04095377

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.
Study: NCT01238211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03496207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
Study: NCT02394600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grastek®
Description: one tablet daily for four months
Study: NCT04396951

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active external overheating with heating plate, Aragonia ® MTC 400
Description: It is a heating device that is adjustable in height up to 50 cm from the patient and generates radiant heat at low temperature (up to 39 ◦C) distributed evenly. It is equipped with an adjustable 0-9 potentiometer and has a skin temperature probe as a control and safety mechanism Measure during 6 hours with indirect calorimetry in first week
Study: NCT04325061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
Study: NCT04155957

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Recovery Rehabilitation Programme
Description: Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises.
Study: NCT04396951

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active external overheating with air blanket, Equator Level 1® de Smiths Medical
Description: Composed of a unit that produces hot air and forced air adjustable from 38ºC to 43ºC. Sends hot forced air distributed by tubular blanket that convectively heats the patient by diffusing hot air directed at the patient through the textile pore of the air blanket Measure during 6 hours with indirect calorimetry in first week
Study: NCT00680316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase alfa
Description: 2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
Study: NCT01704339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA
Description: Single treatment with topical capsaicin 8%
Study: NCT04023006

Intervention type: DEVICE
Intervention: Removable prostheses
Description: Full dentures created by Additive manufacturing (Carbon Printers)
Study: NCT02465229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal tissue-sampling methods before and after stricture dilation
Description: Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
Study: NCT01958151

Intervention type: OTHER
Intervention: State-Trait Anxiety Inventory Scores
Description: Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
Study: NCT00793208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: semi-allogeneic human fibroblasts (MRC-5) transfected with DNA
Description: Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site.
Study: NCT00438516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse home visitation
Description: Nurse home visits from midway through pregnancy to child age 2
Study: NCT03449602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-thoracoscopy
Description: Thoracoscopic pleural biopsy with the mini-thoracoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rigid thoraoscopy
Description: Thoracoscopic pleural biopsy with the conventional rigid thoraoscope
Study: NCT03989817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasoactive Intestinal Peptide (VIP) and Saline
Description: 12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasoactive Intestinal Peptide (VIP) and Saline
Description: 12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
Study: NCT04638010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer control navigation (CNN)
Description: Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General referral (usual care)
Description: Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General referral (usual care)
Description: Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
Study: NCT03594994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Extend time-in-bed by one hour
Study: NCT05274945

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation chemotherapy
Description: 6 cycles of FOLFOX or CAPOX

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME or APR
Description: total mesorectal excision or abdominoperineal resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME or APR
Description: total mesorectal excision or abdominoperineal resection
Study: NCT01745263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 2000 IU/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 2000 IU/d
Study: NCT04155957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Recovery Rehabilitation Programme
Description: Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReHub
Description: Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely.
Study: NCT04160676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone, Ascorbic acid, Thiamine
Description: Combination of hydrocortisone, ascorbic acid, and thiamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study: NCT03970382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoTCR-P1 adoptive cell therapy
Description: The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoTCR-P1 adoptive cell therapy
Description: The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoTCR-P1 adoptive cell therapy
Description: The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 is a biologic response modifier. It is a type of protein called a cytokine.
Study: NCT04722081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: physical therapy-specific exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: physical therapy-specific exercises
Study: NCT03628222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB-TBLB
Description: ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools.~The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray.~TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray-TBLB
Description: Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
Study: NCT04093973

Intervention type: DIAGNOSTIC_TEST
Intervention: bicycle stress echocardiography
Description: Study subjects will perform supine bicycle exercise with echocardiography performed before, during, and after exercise. Definity (perflutren microbubble contrast agent) will be used as needed to enhance echo images.

Intervention type: DIAGNOSTIC_TEST
Intervention: bicycle stress echocardiography
Description: Study subjects will perform supine bicycle exercise with echocardiography performed before, during, and after exercise. Definity (perflutren microbubble contrast agent) will be used as needed to enhance echo images.